» Articles » PMID: 23183896

Cutting Edge: Tumor-targeting Antibodies Enhance NKG2D-mediated NK Cell Cytotoxicity by Stabilizing NK Cell-tumor Cell Interactions

Overview
Journal J Immunol
Date 2012 Nov 28
PMID 23183896
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibodies represent a promising approach to fight a variety of tumors, but their mode of action remains to be fully understood. NK cells can recognize Ab-coated targets, as well as stress ligands, on tumor cells. In this study, we investigated how NK cells integrate both kinds of activating signals. NK cell-mediated killing was maximal with the combined recognition of NKG2D ligands and Ab; surprisingly, only NKG2D engagement substantially enhanced degranulation. Conversely, Ab recognition by NK cells uniquely increased contact stability with tumor cells. Furthermore, using intravital imaging of solid tumors, we showed that Ab recognition favored prolonged interactions between NK cells and targets. Altogether, our results demonstrate that NK cell-mediated killing can be differentially regulated at the level of degranulation and contact stability by distinct activating receptors. Thus, complementary signals mediated by recognition of stress ligands and tumor-specific Abs may contribute to the efficacy of NK cells during mAb therapy.

Citing Articles

Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy.

Yang M, Hou S, Chen Y, Chen H, Chu M, Liu S Cancer Immunol Immunother. 2025; 74(3):100.

PMID: 39904769 PMC: 11794739. DOI: 10.1007/s00262-025-03944-1.


Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.

Patel S, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer N J Immunother Cancer. 2024; 12(2).

PMID: 38309722 PMC: 10840023. DOI: 10.1136/jitc-2023-007340.


αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.

Pan M, Wang F, Nan L, Yang S, Qi J, Xie J Cancer Immunol Immunother. 2022; 72(4):969-984.

PMID: 36227341 PMC: 10991987. DOI: 10.1007/s00262-022-03306-1.


Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.

Tarannum M, Romee R, Shapiro R Front Immunol. 2022; 13:859177.

PMID: 35401529 PMC: 8990319. DOI: 10.3389/fimmu.2022.859177.


CD39/CD73 Dysregulation of Adenosine Metabolism Increases Decidual Natural Killer Cell Cytotoxicity: Implications in Unexplained Recurrent Spontaneous Abortion.

Zhu J, Song G, Zhou X, Han T, Yu X, Chen H Front Immunol. 2022; 13:813218.

PMID: 35222389 PMC: 8866181. DOI: 10.3389/fimmu.2022.813218.